Seeing is Worse than Believing: Reading People’s Minds Better than Computer-Vision Methods Recognize Actions

We had human subjects perform a one-out-of-six class action recognition task from video stimuli while undergoing functional magnetic resonance imaging (fMRI). Support-vector machines (SVMs) were trained on the recovered brain scans to classify actions observed during imaging, yielding average classification accuracy of 69.73% when tested on scans from the same subject and of 34.80% when tested on scans from different subjects. An apples-to-apples comparison was performed with all publicly available software that implements state-of-the-art action recognition on the same video corpus with the same cross-validation regimen and same partitioning into training and test sets, yielding classification accuracies between 31.25% and 52.34%. This indicates that one can read people’s minds better than state-of-the-art computer-vision methods can perform action recognition.This work was supported, in part, by the Center for Brains, Minds and Machines (CBMM), funded by NSF STC award CCF - 1231216. AB, DPB, NS, and JMS were supported, in part, by Army Research Laboratory (ARL) Cooperative Agreement W911NF-10-2-0060, AB, in part, by the Center forBrains, Minds and Machines (CBMM), funded by NSF STC award CCF-1231216, WC, CX, and JJC, in part, by ARL Cooperative Agreement W911NF-10-2-0062 and NSF CAREER grant IIS-0845282, CDF, in part, by NSF grant CNS-0855157, CH and SJH, in part, by the McDonnell Foundation, and BAP, in part, by Science Foundation Ireland grant 09/IN.1/I2637

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms responsible for the drugs\u27 therapeutic effects, namely blockade of inhibitory mechanisms that suppress the immune system and protect body tissues from an unconstrained acute or chronic immune response. Skin, gut, endocrine, lung and musculoskeletal irAEs are relatively common, whereas cardiovascular, hematologic, renal, neurologic and ophthalmologic irAEs occur much less frequently. The majority of irAEs are mild to moderate in severity; however, serious and occasionally life-threatening irAEs are reported in the literature, and treatment-related deaths occur in up to 2% of patients, varying by ICI. Immunotherapy-related irAEs typically have a delayed onset and prolonged duration compared to adverse events from chemotherapy, and effective management depends on early recognition and prompt intervention with immune suppression and/or immunomodulatory strategies. There is an urgent need for multidisciplinary guidance reflecting broad-based perspectives on how to recognize, report and manage organ-specific toxicities until evidence-based data are available to inform clinical decision-making. The Society for Immunotherapy of Cancer (SITC) established a multidisciplinary Toxicity Management Working Group, which met for a full-day workshop to develop recommendations to standardize management of irAEs. Here we present their consensus recommendations on managing toxicities associated with immune checkpoint inhibitor therapy